NR2C2

NR2C2 (TR4) is a ligand-regulated orphan nuclear receptor that functions as a transcriptional activator and repressor across diverse biological processes including erythropoiesis, gluconeogenesis, and neuroendocrine signaling. As a heterodimer with TR2, it constitutes the DRED repressor complex that binds DR1 elements in embryonic and fetal globin gene promoters and the GATA1 hematopoietic enhancer to silence these genes in definitive erythroid cells (PMID:12093744, PMID:17974920). The ligand-binding domain adopts an autorepressed conformation in the absence of ligand, with retinol and retinoic acid promoting coactivator recruitment and transcriptional activation of target genes including PEPCK and POMC (PMID:21068381, PMID:17827404, PMID:23653479). TR4 activity is modulated by MAPK-mediated phosphorylation, CUL4B/DDB1/DCAF1-dependent ubiquitin-mediated degradation, protein–protein interaction with estrogen receptor to suppress ER signaling, and cofactor interactions such as with the repressor TIP27 (PMID:23653479, PMID:28623141, PMID:11844790, PMID:15302918).

1. 1994 Medium

   Cloning of NR2C2 (TR4) established the existence of a novel nuclear receptor closely related to TR2 with enriched expression in brain and reproductive tissues, raising the question of its transcriptional targets and functions.

   Evidence cDNA library screening from hypothalamus, prostate, and testis; tissue expression profiling

   PMID:8016112

   Open questions at the time

   • No target genes or DNA-binding specificity identified
   • Ligand unknown
   • Single-lab cloning without independent confirmation at the time
2. 2002 High

   Identification of the TR2/TR4 (DRED) heterodimer as the repressor of embryonic and fetal globin genes via DR1 elements provided the first functional role for NR2C2 in erythroid gene regulation and connected it to hereditary persistence of fetal hemoglobin pathogenesis.

   Evidence Co-IP, EMSA, size-exclusion chromatography, transgenic mouse overexpression

   PMID:12093744

   Open questions at the time

   • Corepressor components of the ~540 kDa DRED complex not identified
   • In vivo loss-of-function in erythroid lineage not yet shown
3. 2002 High

   Demonstration that TR4 suppresses estrogen receptor transactivation through direct protein–protein interaction that blocks ER dimerization revealed a non-DNA-binding mechanism by which TR4 modulates hormone signaling.

   Evidence GST pull-down, EMSA, stable transfection in MCF-7 cells, proliferation assay

   PMID:11844790

   Open questions at the time

   • Physiological relevance in vivo not established
   • Stoichiometry and structural basis of TR4–ER interaction unknown
4. 2004 High

   Discovery of the corepressor TIP27 as a direct LBD-interacting partner that represses TR4 transactivation without disrupting DNA binding indicated that TR4 activity is modulated by cofactor competition at the LBD surface.

   Evidence Yeast two-hybrid, mammalian two-hybrid, pull-down, confocal co-localization, reporter assay

   PMID:15302918

   Open questions at the time

   • Endogenous stoichiometry of TIP27–TR4 complex unknown
   • No in vivo loss-of-function for TIP27
5. 2007 High

   TR4 was shown to directly activate PEPCK transcription and repress GATA1 transcription via cognate DR elements, establishing it as a bifunctional regulator of both metabolic (gluconeogenesis) and hematopoietic gene programs, validated in knockout mice.

   Evidence ChIP, EMSA, luciferase reporter, siRNA, TR4 KO mice, TR2/TR4-null and GOF transgenic mice, shRNA in CD34+ cells

   PMID:17827404 PMID:17974920

   Open questions at the time

   • How context-dependent switching between activation and repression is determined remains unclear
   • Genome-wide target repertoire not yet defined
6. 2010 High

   The crystal structure of the TR4 LBD revealed an autorepressed conformation with an occluded coactivator groove, and retinol/retinoic acid were identified as ligands that relieve autoinhibition and promote coactivator recruitment, resolving the long-standing question of whether TR4 is ligand-regulated.

   Evidence X-ray crystallography, coactivator recruitment assay, transcriptional reporter, mutagenesis

   PMID:21068381

   Open questions at the time

   • Physiological retinoid concentrations required for activation in vivo not determined
   • No co-crystal structure with ligand
7. 2010 Medium

   Genome-wide ChIP-seq revealed that the majority of TR4 binding sites lack canonical DR1 motifs and overlap with ETS factor binding sites, suggesting alternative chromatin recruitment mechanisms beyond direct DNA recognition.

   Evidence ChIP-seq in four human cell lines with motif and co-occupancy analysis

   PMID:21126370

   Open questions at the time

   • Direct physical interaction between TR4 and ETS factors not demonstrated
   • Functional significance of non-DR1 sites not validated
8. 2013 High

   TR4 was found to activate POMC transcription via a DR1 element and to be potentiated by MAPK-mediated phosphorylation, linking TR4 to HPA-axis regulation and establishing phosphorylation as a post-translational activating mechanism.

   Evidence ChIP, luciferase reporter, overexpression/knockdown in corticotroph cells, in vivo mouse tumor model, MAPK phosphorylation assay

   PMID:23653479

   Open questions at the time

   • Specific phosphorylation sites and responsible MAPK family member not fully characterized
   • Relevance to normal pituitary physiology versus tumor context unclear
9. 2017 Medium

   Identification of CUL4B/DDB1/DCAF1 as the E3 ligase targeting TR4 for ubiquitin-dependent degradation, modulated by SIRT7-mediated DDB1 deacetylation, established a proteostatic regulatory layer for TR4 protein levels.

   Evidence Co-IP, K1121R mutagenesis of DDB1, western blot, qPCR of TR4 target genes

   PMID:28623141

   Open questions at the time

   • Direct ubiquitination of TR4 not demonstrated with in vitro reconstitution
   • Specific ubiquitinated lysine residues on TR4 not mapped
10. 2018 Medium

    Multiple cancer-context studies showed that TR4 transcriptionally controls diverse downstream effectors (EphA2 in HCC, QKI/circZEB1 axis in prostate cancer, lncTASR/AXL in RCC), implicating TR4 in tumor invasion and therapy resistance through cell-type-specific target gene programs.

    Evidence ChIP, luciferase reporter, shRNA/siRNA knockdown, in vivo xenograft and orthotopic models across multiple cancer types

    PMID:29449527 PMID:31501521 PMID:32768524

    Open questions at the time

    • Mechanisms determining cell-type-specific target selection are unknown
    • Therapeutic targeting of TR4 in cancer not clinically validated
    • Findings largely from single-lab studies

• Key unresolved questions include the full spectrum of physiological TR4 ligands, the structural basis of TR2/TR4 heterodimerization and DRED complex assembly, and the mechanisms governing context-dependent switching between transcriptional activation and repression.
• No co-crystal structure of TR4 LBD with retinoid ligand
• DRED complex corepressor subunit identities unknown
• No systematic loss-of-function studies in adult tissues beyond erythroid and metabolic contexts